1. Executive Summary (Confidence: High)

B-Flexion operates as a sophisticated investment vehicle that bridges the gap between traditional family-office capital and institutional-grade private equity. With a heritage spanning three generations, the firm has transitioned from its origins in biopharmaceuticals to become a global orchestrator of capital across Europe and the United States.^[1] The organization is characterized by its "active owner" philosophy, which mandates deep involvement in the operational and strategic trajectories of its portfolio companies, particularly within the life sciences sector. A definitive example of this approach is the firm's recent strategic maneuver to acquire the remaining 57% interest in Radius Health, a move designed to consolidate ownership of a now-profitable biopharmaceutical entity for its next phase of commercial expansion.^[3] This acquisition, slated to close in early 2026, underscores B-Flexion’s commitment to the longevity sector, specifically addressing age-related skeletal health.^[4] Beyond direct holdings, B-Flexion seeds and builds asset managers, creating a diversified ecosystem that includes private equity, venture capital, and infrastructure, thereby ensuring resilience across various economic cycles.